503A vs 503B compounding: how the rules differ

Sections 503A and 503B set different rules for compounding pharmacies and outsourcing facilities, and this guide explains each, with the peptides FDA names, as of November 17, 2026.

Basics7 min read

Key takeaway

A 503A compounder is a state-licensed pharmacy, federal facility or physician compounding for an identified patient on a valid prescription. A 503B outsourcing facility registers with FDA, must meet current good manufacturing practice and may compound with or without patient prescriptions. Each may use bulk drug substances only under its own section’s rules. The 503B clinical-need list held five substances, none of them peptides, when we checked. In October 2026, HHS also published a draft, non-binding policy on 503A compounding with certain peptides.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited0
Related productsResearch peptide catalog

503A vs 503B compounding is the split behind most US questions about compounded peptides. Two sections of the Federal Food, Drug, and Cosmetic Act set different rules for pharmacies and outsourcing facilities, including which bulk ingredients each may use. Sources were checked on November 17, 2026.

Quick answer: 503A pharmacies compound for individual patients on prescriptions, overseen mainly by state boards of pharmacy. 503B outsourcing facilities register with FDA, follow manufacturing standards and are inspected by FDA. A 503A compounder may use a bulk substance if it has a USP or NF monograph, is a component of an FDA-approved drug, or is on the 503A bulks list. A 503B facility may use one only if it is on the 503B bulks list or the drug is on FDA’s shortage list. Either way, compounded drugs are not FDA-approved.

This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.

What is a 503A pharmacy?

Section 503A (21 U.S.C. 353a) covers drugs “compounded for an identified individual patient based on the receipt of a valid prescription order.” FDA describes the compounder as a licensed pharmacist in a state-licensed pharmacy or federal facility, or a physician. These compounders are not subject to current good manufacturing practice (CGMP) requirements, and state boards of pharmacy have primary day-to-day oversight (FDA, 2025).

When all of 503A’s conditions are met, the drug is exempt from the CGMP, adequate-directions and FDA approval requirements. When any condition is not met, those exemptions do not apply.

What is a 503B outsourcing facility?

FDA describes outsourcing facilities as “a category of compounders established in 2013 by the Drug Quality and Security Act.” They register with FDA, are subject to CGMP requirements and are inspected by FDA on a risk-based schedule (FDA, 2025).

Section 503B (21 U.S.C. 353b) requires that drugs be compounded “by or under the direct supervision of a licensed pharmacist.” An outsourcing facility is a facility “at one geographic location or address” engaged in sterile compounding. It “is not required to be a licensed pharmacy” and “may or may not obtain prescriptions for identified individual patients.” Its drugs are exempt from the approval, adequate-directions and certain supply-chain tracing requirements, but not from CGMP. Table 1 compares the two.

Table 1

503A pharmacies and 503B outsourcing facilities compared

Feature 503A 503B
Who compounds Licensed pharmacist in a state-licensed pharmacy or federal facility, or a physician Registered outsourcing facility, under a licensed pharmacist’s direct supervision
Prescriptions For an identified individual patient, on a valid prescription May or may not obtain patient prescriptions
Main oversight State boards of pharmacy FDA registration and risk-based inspection
CGMP Not subject to CGMP Subject to CGMP
Bulk drug substances USP or NF monograph, component of an approved drug, or on the 503A bulks list On the 503B bulks list (clinical need), or the drug is on FDA’s shortage list
Copies of approved drugs Not “regularly or in inordinate amounts” Not allowed, unless the approved drug is on the shortage list
FDA approval of the compounded drug None None

How are bulk drug substances listed for 503A?

The statute sets three routes in order. A bulk drug substance must comply with an applicable USP or NF monograph. If none exists, it must be a component of an FDA-approved drug. If it is neither, it must appear on a list FDA develops through regulations, called the 503A bulks list (FDA, 2026). Our article on peptides and 503A compounding has more background.

How are bulk drug substances listed for 503B?

Under section 503B, a bulk drug substance must appear on a list of substances “for which there is a clinical need,” or the drug compounded from it must appear on FDA’s drug shortage list “at the time of compounding, distribution, and dispensing.” Listing requires a Federal Register proposal and at least 60 days for comment.

FDA’s page lists five substances: diphenylcyclopropenone, glycolic acid, quinacrine hydrochloride, squaric acid dibutyl ester and trichloroacetic acid, each with use limits. FDA decided not to include more than 20 others, among them vasopressin (FDA, 2024).

What are FDA’s categories for nominated substances?

While FDA reviews nominations, its interim policies sort each nominated substance into one of three categories, for both 503A and 503B:

  • Category 1: under evaluation. FDA does not intend to take action against compounders using these substances if the guidance conditions are met.
  • Category 2: FDA has identified “significant safety risks relating to the use of these substances in compounding.”
  • Category 3: nominated with “insufficient supporting information for FDA to evaluate them.”

Category 1 is not approval or a place on a bulks list; it reflects an interim enforcement policy (FDA, 2025). FDA also keeps a separate table of substances whose nominations were withdrawn.

How do drug shortage rules work?

Under 503A, a pharmacy may not compound “regularly or in inordinate amounts” drugs that are essentially copies of a commercially available drug product. FDA does not treat a drug on its shortage list as commercially available, so that limit does not apply while the shortage lasts (FDA, 2025). In its April 2026 GLP-1 policy, FDA said it does not intend to act against a 503A compounder that fills four or fewer prescriptions of such a copy in a calendar month (FDA, 2026).

Under 503B, a facility may compound from a bulk substance when the drug is on the shortage list, and the ban on copying an approved drug does not apply to a drug on that list. When a drug comes off the list, FDA says it may act if a facility keeps filling new orders, or fills existing orders more than 60 days after removal.

How does this apply to peptides?

FDA names peptides at each stage of this system:

  • Semaglutide and tirzepatide: FDA declared the shortages resolved in February 2025 and December 2024. On April 1, 2026, FDA wrote: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding “no clinical need” (FDA, 2026). The comment period was extended to July 30, 2026 (91 FR 38719). We found no final decision.
  • Category 2 peptides: kisspeptin-10 for 503A, and GHRP-2, GHRP-6 and ipamorelin acetate for 503B (FDA, 2026).
  • Withdrawn nominations: FDA lists BPC-157, AOD-9604, CJC-1295, KPV, melanotan II, MOTS-c, TB-500 and thymosin alpha-1, among others.
  • Advisory committee review: at the July 23, 2026 meeting, FDA staff proposed that BPC-157, KPV, TB-500 and MOTS-c “NOT be included on the 503A Bulks List” (FDA, 2026). The committee advises; FDA decides. We found no final decision.
  • 503A category 1: includes GHK-Cu for non-injectable routes, glutathione and vasoactive intestinal peptide. FDA plans to consult its advisory committee on GHK-Cu before the end of February 2027 (FDA, 2026).

Our pages on compounded semaglutide and compounded tirzepatide cover those two cases in detail.

What is the October 2026 HHS draft peptide policy?

On October 30, 2026, the HHS Office of the Secretary published a notice of availability for a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (91 FR 68526). It covers 503A compounding only, not 503B. The notice says HHS “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A.” It applies while the 503A bulks list “is developed through rulemaking.”

Three limits matter. The notice calls it a draft, interim policy that “is not binding on HHS or the public.” HHS may revisit it if “a safety signal or product quality issue arises.” And the peptides are not named in the Federal Register text; they are in Appendix A of the policy document on the HHS website. Comments were open for two weeks under docket HHS-OASH-2026-0496, and as of November 17, 2026 we found no final version. FDA’s future rulemakings “may propose adding some or all of these peptides to the 503A bulks list.” Enforcement discretion is neither a place on that list nor FDA approval.

Frequently asked questions about 503A and 503B compounding

Is a compounded drug FDA-approved?

No. FDA states that compounded drugs are not FDA-approved, under either section.

Does a 503B facility need a prescription for each patient?

The statute says an outsourcing facility “may or may not obtain prescriptions for identified individual patients.” A 503A pharmacy compounds for an identified patient on a valid prescription.

Is Vitrapep a compounding pharmacy?

No. Vitrapep is not a 503A compounding pharmacy or a 503B outsourcing facility. We sell research peptides for laboratory research use only, not for human or veterinary use.

What to know now

  • 503A: patient prescriptions, state board oversight; bulks need a monograph, an approved-drug component or the 503A list.
  • 503B: FDA registration and CGMP; bulks need the clinical-need list or the shortage list.
  • Categories: 1 under evaluation, 2 significant safety risks, 3 insufficient support.
  • Peptides: semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list.
  • HHS draft policy: October 30, 2026; covers peptides in its Appendix A; not binding, not final.

What we’re watching

Whether HHS finalizes, changes or withdraws its draft peptide policy. FDA’s final decision on semaglutide, tirzepatide and liraglutide for the 503B bulks list. Any FDA decision on BPC-157, KPV, TB-500 and MOTS-c. And the GHK-Cu advisory committee consultation planned before the end of February 2027.

Also in the library

Sources: United States Code. 21 U.S.C. 353a: Pharmacy compounding, 21 U.S.C. 353a: Pharmacy compounding; United States Code. 21 U.S.C. 353b: Outsourcing facilities, 21 U.S.C. 353b: Outsourcing facilities; U.S. Food and Drug Administration 2025, Compounding and the FDA: Questions and answers; U.S. Food and Drug Administration 2026, Bulk drug substances used in compounding under section 503A of the FD&C Act; U.S. Food and Drug Administration 2025, Bulk drug substances used in compounding under section 503B of the FD&C Act; U.S. Food and Drug Administration 2024, 503B bulk drug substances list; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2025; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2025, Compounding when drugs are on FDA’s drug shortages list; U.S. Food and Drug Administration 2026, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize; U.S. Food and Drug Administration 2026, FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list; Food and Drug Administration 2026, Federal Register, 91; Office of the Secretary 2026, Federal Register, 91; U.S. Food and Drug Administration 2026, Pharmacy Compounding Advisory Committee meeting: FDA presentations. All 15 citations

Back to the research library

References

  1. United States Code. 21 U.S.C. 353a: Pharmacy compounding (2023 edition). GovInfo, U.S. Government Publishing Office. https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec353a.htm
  2. United States Code. 21 U.S.C. 353b: Outsourcing facilities (2023 edition). GovInfo, U.S. Government Publishing Office. https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec353b.htm
  3. U.S. Food and Drug Administration. (2025). Compounding and the FDA: Questions and answers (content current as of September 16, 2025). https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  4. U.S. Food and Drug Administration. (2026). Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of May 14, 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  5. U.S. Food and Drug Administration. (2025). Bulk drug substances used in compounding under section 503B of the FD&C Act (content current as of January 7, 2025). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
  6. U.S. Food and Drug Administration. (2024). 503B bulk drug substances list (content current as of May 16, 2024). https://www.fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
  7. U.S. Food and Drug Administration. (2026, May 14). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/media/94155/download
  8. U.S. Food and Drug Administration. (2025, March 21). Bulk drug substances nominated for use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/media/94164/download
  9. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  10. U.S. Food and Drug Administration. (2025). Compounding when drugs are on FDA’s drug shortages list (content current as of August 8, 2025). https://www.fda.gov/drugs/human-drug-compounding/compounding-when-drugs-are-fdas-drug-shortages-list
  11. U.S. Food and Drug Administration. (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  12. U.S. Food and Drug Administration. (2026, April 30). FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  13. Food and Drug Administration. (2026, June 26). List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act; extension of comment period. Federal Register, 91, 38719. https://www.govinfo.gov/content/pkg/FR-2026-06-26/html/2026-12937.htm
  14. Office of the Secretary, U.S. Department of Health and Human Services. (2026, October 30). Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances; notice of availability (Docket No. HHS-OASH-2026-0496). Federal Register, 91, 68526. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  15. U.S. Food and Drug Administration. (2026, July 23). Pharmacy Compounding Advisory Committee meeting: FDA presentations. https://www.fda.gov/media/193773/download